Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | KTE-C19 |
Trade Name | Yescarta |
Synonyms | KTE-C19 CAR|axicabtagene ciloleucel |
Drug Descriptions |
Yescarta (KTE-C19) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (Blood 2015 126:3991). Yescarta (KTE-C19) is FDA approved for treatment of relapsed or refractory large B-cell lymphoma (FDA.gov). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C120309 |